hVIVO (LON:HVO) Shares Down 46.3% - Time to Sell?

hVIVO plc (LON:HVO - Get Free Report) shares dropped 46.3% during mid-day trading on Saturday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares were traded during mid-day trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Upgrades and Downgrades

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Price Performance

The stock has a market capitalization of £73.59 million, a PE ratio of 4.29 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock's 50 day moving average price is GBX 15.92 and its 200-day moving average price is GBX 17.70.

hVIVO (LON:HVO - Get Free Report) last issued its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, equities analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Activity at hVIVO

In related news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($705,491.02). 14.03% of the stock is currently owned by corporate insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.